| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Platelets | 23 | 2016 | 676 | 1.180 |
Why?
|
| Thrombosis | 4 | 2023 | 744 | 1.070 |
Why?
|
| Platelet Aggregation | 17 | 2016 | 182 | 0.970 |
Why?
|
| Venous Thromboembolism | 6 | 2023 | 376 | 0.900 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2023 | 8 | 0.860 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2022 | 46 | 0.800 |
Why?
|
| von Willebrand Factor | 13 | 2014 | 245 | 0.780 |
Why?
|
| Thrombocytopenia | 4 | 2020 | 870 | 0.760 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2019 | 79 | 0.650 |
Why?
|
| Neoplasms | 8 | 2024 | 15897 | 0.560 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2011 | 325 | 0.540 |
Why?
|
| Anticoagulants | 4 | 2023 | 776 | 0.530 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 7 | 2004 | 69 | 0.460 |
Why?
|
| Heparin | 1 | 2016 | 342 | 0.460 |
Why?
|
| Platelet Activation | 5 | 2016 | 100 | 0.390 |
Why?
|
| Polycythemia Vera | 1 | 2014 | 268 | 0.390 |
Why?
|
| Platelet Membrane Glycoproteins | 5 | 1996 | 64 | 0.390 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 1948 | 0.360 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 14622 | 0.350 |
Why?
|
| Thrombin | 7 | 2007 | 91 | 0.350 |
Why?
|
| Platelet Count | 6 | 2020 | 491 | 0.320 |
Why?
|
| Receptors, Thrombin | 1 | 2007 | 19 | 0.300 |
Why?
|
| Contractile Proteins | 2 | 2004 | 44 | 0.300 |
Why?
|
| Receptor, PAR-1 | 1 | 2007 | 32 | 0.300 |
Why?
|
| Sarcoma, Kaposi | 2 | 1999 | 190 | 0.270 |
Why?
|
| Cardiac Catheterization | 1 | 2011 | 669 | 0.270 |
Why?
|
| Endovascular Procedures | 1 | 2011 | 472 | 0.250 |
Why?
|
| Microfilament Proteins | 2 | 2004 | 495 | 0.240 |
Why?
|
| Blood Platelet Disorders | 1 | 2005 | 35 | 0.240 |
Why?
|
| Acetylcysteine | 1 | 2004 | 136 | 0.230 |
Why?
|
| Smoldering Multiple Myeloma | 1 | 2023 | 10 | 0.220 |
Why?
|
| Complement Activation | 2 | 2014 | 92 | 0.220 |
Why?
|
| Complement System Proteins | 2 | 2014 | 134 | 0.210 |
Why?
|
| Epistaxis | 1 | 2023 | 32 | 0.210 |
Why?
|
| Thrombectomy | 1 | 2024 | 169 | 0.210 |
Why?
|
| Stress, Mechanical | 9 | 2008 | 273 | 0.210 |
Why?
|
| Fibrinogen | 3 | 2014 | 213 | 0.200 |
Why?
|
| ADAM Proteins | 3 | 2013 | 114 | 0.200 |
Why?
|
| Protein Kinase C | 5 | 2002 | 411 | 0.200 |
Why?
|
| Humans | 55 | 2024 | 270370 | 0.200 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2002 | 63 | 0.190 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2003 | 307 | 0.190 |
Why?
|
| Cell Membrane | 1 | 2004 | 882 | 0.190 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 2912 | 0.190 |
Why?
|
| Hypersplenism | 1 | 2020 | 23 | 0.180 |
Why?
|
| Venous Thrombosis | 1 | 2024 | 381 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 2075 | 0.170 |
Why?
|
| Thromboplastin | 1 | 2019 | 33 | 0.170 |
Why?
|
| Signal Transduction | 8 | 2018 | 12100 | 0.170 |
Why?
|
| Tyrosine | 3 | 2003 | 509 | 0.160 |
Why?
|
| Coronary Artery Bypass | 1 | 2002 | 531 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2023 | 620 | 0.150 |
Why?
|
| Calcium | 4 | 1996 | 1587 | 0.150 |
Why?
|
| Adenosine Diphosphate | 4 | 2016 | 100 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1999 | 180 | 0.150 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 2221 | 0.150 |
Why?
|
| Complement Factor H | 2 | 2013 | 28 | 0.140 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2007 | 69 | 0.140 |
Why?
|
| Genital Neoplasms, Female | 2 | 2015 | 788 | 0.140 |
Why?
|
| In Vitro Techniques | 6 | 2007 | 1716 | 0.140 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 90 | 0.140 |
Why?
|
| Hemorrhage | 2 | 2023 | 724 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2023 | 797 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2002 | 1066 | 0.130 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1998 | 366 | 0.130 |
Why?
|
| HIV Infections | 3 | 2003 | 2150 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 1516 | 0.130 |
Why?
|
| Evolution, Molecular | 1 | 2019 | 867 | 0.130 |
Why?
|
| Enzyme Activation | 5 | 2007 | 1814 | 0.130 |
Why?
|
| Phosphorylation | 9 | 2007 | 4947 | 0.120 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 605 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2006 | 1839 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 7271 | 0.120 |
Why?
|
| von Willebrand Diseases | 1 | 2015 | 55 | 0.120 |
Why?
|
| Cytokines | 1 | 2023 | 2822 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2018 | 2475 | 0.120 |
Why?
|
| Phosphatidic Acids | 3 | 1992 | 14 | 0.120 |
Why?
|
| Risk Factors | 5 | 2023 | 17832 | 0.110 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2013 | 48 | 0.110 |
Why?
|
| Incidence | 4 | 2015 | 5812 | 0.100 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2012 | 62 | 0.100 |
Why?
|
| Complement C3 | 1 | 2012 | 80 | 0.100 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1993 | 149 | 0.100 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2012 | 63 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2007 | 1710 | 0.100 |
Why?
|
| Time Factors | 5 | 2014 | 12989 | 0.100 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 2281 | 0.100 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 1995 | 328 | 0.090 |
Why?
|
| Bone Marrow | 1 | 1999 | 2439 | 0.090 |
Why?
|
| Th1 Cells | 1 | 2012 | 259 | 0.090 |
Why?
|
| Th17 Cells | 1 | 2012 | 163 | 0.090 |
Why?
|
| Guideline Adherence | 1 | 2015 | 627 | 0.090 |
Why?
|
| CHO Cells | 3 | 2006 | 319 | 0.090 |
Why?
|
| Receptors, Purinergic P2Y12 | 2 | 2007 | 13 | 0.090 |
Why?
|
| Blotting, Western | 4 | 2013 | 3592 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2023 | 3550 | 0.090 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 908 | 0.090 |
Why?
|
| Cricetinae | 3 | 2006 | 769 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2018 | 1539 | 0.080 |
Why?
|
| Oligopeptides | 2 | 2007 | 447 | 0.080 |
Why?
|
| Second Messenger Systems | 1 | 1989 | 35 | 0.080 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 30934 | 0.080 |
Why?
|
| Egtazic Acid | 3 | 1994 | 58 | 0.080 |
Why?
|
| Platelet Transfusion | 2 | 2012 | 166 | 0.080 |
Why?
|
| Adult | 14 | 2024 | 81727 | 0.080 |
Why?
|
| Mechanotransduction, Cellular | 2 | 2006 | 87 | 0.080 |
Why?
|
| Models, Biological | 1 | 2017 | 3196 | 0.080 |
Why?
|
| Ovarian Neoplasms | 2 | 2016 | 4785 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 4960 | 0.080 |
Why?
|
| Male | 14 | 2024 | 128053 | 0.080 |
Why?
|
| Platelet Adhesiveness | 1 | 2008 | 45 | 0.080 |
Why?
|
| Filamins | 2 | 2004 | 33 | 0.080 |
Why?
|
| Texas | 3 | 2015 | 6432 | 0.080 |
Why?
|
| Magnesium Sulfate | 1 | 2008 | 55 | 0.070 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2007 | 35 | 0.070 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2007 | 29 | 0.070 |
Why?
|
| Type C Phospholipases | 1 | 2007 | 62 | 0.070 |
Why?
|
| Middle Aged | 9 | 2024 | 90068 | 0.070 |
Why?
|
| Cytoskeleton | 2 | 2006 | 297 | 0.070 |
Why?
|
| Receptor Cross-Talk | 1 | 2007 | 79 | 0.070 |
Why?
|
| Animals | 12 | 2019 | 61992 | 0.070 |
Why?
|
| Cyclic AMP | 1 | 1988 | 383 | 0.070 |
Why?
|
| P-Selectin | 1 | 2007 | 110 | 0.070 |
Why?
|
| ADAMTS13 Protein | 3 | 2013 | 71 | 0.070 |
Why?
|
| Prevalence | 1 | 2014 | 3355 | 0.070 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 1161 | 0.070 |
Why?
|
| Actinin | 2 | 2006 | 20 | 0.070 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 2027 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7370 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2024 | 39744 | 0.070 |
Why?
|
| Cells, Cultured | 9 | 2013 | 5690 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 1999 | 2664 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2018 | 3662 | 0.070 |
Why?
|
| Blood Viscosity | 3 | 1995 | 19 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 293 | 0.060 |
Why?
|
| Hospitalization | 1 | 2015 | 2162 | 0.060 |
Why?
|
| Bleeding Time | 1 | 2005 | 12 | 0.060 |
Why?
|
| Brefeldin A | 1 | 2004 | 22 | 0.060 |
Why?
|
| Aged | 8 | 2024 | 73152 | 0.060 |
Why?
|
| Ticlopidine | 1 | 2005 | 49 | 0.060 |
Why?
|
| Female | 14 | 2024 | 148592 | 0.060 |
Why?
|
| Hemostatics | 1 | 2005 | 82 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2005 | 175 | 0.060 |
Why?
|
| Acetyltransferases | 1 | 2004 | 146 | 0.060 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2004 | 77 | 0.060 |
Why?
|
| Young Adult | 4 | 2015 | 22138 | 0.060 |
Why?
|
| Purinergic P2 Receptor Antagonists | 1 | 2003 | 7 | 0.060 |
Why?
|
| Rivaroxaban | 1 | 2023 | 58 | 0.050 |
Why?
|
| Thrombocytosis | 2 | 2016 | 142 | 0.050 |
Why?
|
| Endoplasmic Reticulum | 1 | 2004 | 328 | 0.050 |
Why?
|
| Molecular Weight | 2 | 1994 | 721 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 15191 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2024 | 33701 | 0.050 |
Why?
|
| Autoantigens | 1 | 2004 | 245 | 0.050 |
Why?
|
| Hemorheology | 2 | 2008 | 39 | 0.050 |
Why?
|
| Multiprotein Complexes | 1 | 2004 | 385 | 0.050 |
Why?
|
| Protein Transport | 1 | 2004 | 738 | 0.050 |
Why?
|
| Mice | 3 | 2019 | 35572 | 0.050 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 470 | 0.050 |
Why?
|
| Phosphatidylinositols | 2 | 1992 | 69 | 0.050 |
Why?
|
| Antigens, Bacterial | 1 | 2004 | 364 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2008 | 1037 | 0.050 |
Why?
|
| Aneuploidy | 1 | 2023 | 377 | 0.050 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2002 | 69 | 0.050 |
Why?
|
| Aspirin | 1 | 2004 | 374 | 0.050 |
Why?
|
| Metalloendopeptidases | 1 | 2002 | 176 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 536 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2007 | 3045 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2012 | 2808 | 0.050 |
Why?
|
| Interleukin-1 | 2 | 1993 | 475 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 1995 | 4476 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1993 | 248 | 0.050 |
Why?
|
| Splenic Artery | 1 | 2020 | 54 | 0.040 |
Why?
|
| Phospholipids | 2 | 1993 | 166 | 0.040 |
Why?
|
| Phosphoproteins | 3 | 2006 | 1137 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2012 | 7241 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2023 | 1608 | 0.040 |
Why?
|
| Epoprostenol | 2 | 1991 | 86 | 0.040 |
Why?
|
| Disease Progression | 2 | 2023 | 6828 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2003 | 957 | 0.040 |
Why?
|
| Amino Acid Sequence | 4 | 2003 | 4568 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2015 | 824 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2004 | 1082 | 0.040 |
Why?
|
| Molecular Sequence Data | 4 | 2003 | 6683 | 0.040 |
Why?
|
| Crotalid Venoms | 1 | 1996 | 9 | 0.040 |
Why?
|
| Adolescent | 2 | 2014 | 32661 | 0.030 |
Why?
|
| Phosphatidylinositol 4,5-Diphosphate | 2 | 1992 | 19 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 5071 | 0.030 |
Why?
|
| Shear Strength | 2 | 2006 | 30 | 0.030 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 1995 | 23 | 0.030 |
Why?
|
| Adenine | 1 | 2018 | 668 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 1995 | 68 | 0.030 |
Why?
|
| Guanylate Cyclase | 1 | 1995 | 78 | 0.030 |
Why?
|
| Epinephrine | 1 | 1996 | 249 | 0.030 |
Why?
|
| Syk Kinase | 2 | 2006 | 65 | 0.030 |
Why?
|
| Cytochalasin D | 1 | 1994 | 22 | 0.030 |
Why?
|
| Helicobacter Infections | 1 | 2004 | 1185 | 0.030 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1994 | 88 | 0.030 |
Why?
|
| Helicobacter pylori | 1 | 2004 | 1274 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 1994 | 125 | 0.030 |
Why?
|
| Platelet Storage Pool Deficiency | 1 | 1994 | 3 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2003 | 1484 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 7010 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2014 | 232 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 2394 | 0.030 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2013 | 14 | 0.030 |
Why?
|
| Kinetics | 2 | 1996 | 2220 | 0.030 |
Why?
|
| Recurrence | 1 | 2002 | 4877 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2015 | 13998 | 0.030 |
Why?
|
| Fibrinolysin | 1 | 1993 | 25 | 0.030 |
Why?
|
| Collagen | 1 | 2016 | 727 | 0.030 |
Why?
|
| Homocystinuria | 1 | 1993 | 21 | 0.030 |
Why?
|
| Peptide Mapping | 1 | 1993 | 118 | 0.030 |
Why?
|
| Cations, Divalent | 1 | 1992 | 29 | 0.030 |
Why?
|
| Piperidines | 1 | 2018 | 1086 | 0.030 |
Why?
|
| Immunoblotting | 1 | 1994 | 893 | 0.030 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1993 | 39 | 0.030 |
Why?
|
| Aortic Valve Insufficiency | 1 | 1994 | 141 | 0.030 |
Why?
|
| Diglycerides | 2 | 1991 | 35 | 0.030 |
Why?
|
| Arachidonic Acid | 3 | 2004 | 120 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2003 | 2928 | 0.030 |
Why?
|
| Manganese | 1 | 1992 | 65 | 0.030 |
Why?
|
| Transplantation Chimera | 1 | 2012 | 173 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 3031 | 0.020 |
Why?
|
| Nitric Oxide | 2 | 1993 | 657 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2018 | 2853 | 0.020 |
Why?
|
| Laparotomy | 1 | 2012 | 234 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2015 | 9463 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2012 | 225 | 0.020 |
Why?
|
| Bleomycin | 2 | 2003 | 482 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 1998 | 1585 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2012 | 630 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2023 | 6775 | 0.020 |
Why?
|
| Cell Culture Techniques | 2 | 2008 | 573 | 0.020 |
Why?
|
| Heart Valve Prosthesis | 1 | 1994 | 307 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1994 | 905 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 675 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2015 | 676 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2004 | 5438 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2013 | 598 | 0.020 |
Why?
|
| Thromboxane A2 | 1 | 1989 | 25 | 0.020 |
Why?
|
| Eicosanoic Acids | 1 | 1989 | 4 | 0.020 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2012 | 380 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2006 | 1280 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 4940 | 0.020 |
Why?
|
| Arginine | 1 | 1991 | 508 | 0.020 |
Why?
|
| Proteins | 1 | 1996 | 2042 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 1386 | 0.020 |
Why?
|
| Blood Proteins | 1 | 1989 | 299 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 1640 | 0.020 |
Why?
|
| Cell Shape | 1 | 2008 | 126 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 1557 | 0.020 |
Why?
|
| Magnesium | 1 | 2008 | 172 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1988 | 230 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 2455 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2015 | 919 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 7646 | 0.020 |
Why?
|
| Carrier Proteins | 2 | 1996 | 2100 | 0.020 |
Why?
|
| Prognosis | 2 | 2015 | 22473 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 1989 | 586 | 0.020 |
Why?
|
| Alleles | 1 | 2013 | 2591 | 0.020 |
Why?
|
| Phosphocreatine | 2 | 1996 | 13 | 0.020 |
Why?
|
| Cricetulus | 1 | 2006 | 213 | 0.020 |
Why?
|
| Creatine Kinase | 2 | 1996 | 95 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 4955 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2006 | 116 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2012 | 3044 | 0.020 |
Why?
|
| Lipids | 1 | 1989 | 653 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 10384 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 10261 | 0.020 |
Why?
|
| Doxorubicin | 2 | 2003 | 3144 | 0.020 |
Why?
|
| Myeloproliferative Disorders | 1 | 1993 | 881 | 0.020 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2004 | 15 | 0.020 |
Why?
|
| DNA | 1 | 2013 | 3048 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2015 | 2163 | 0.010 |
Why?
|
| Survival Rate | 1 | 2017 | 12513 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2004 | 261 | 0.010 |
Why?
|
| Homosexuality | 1 | 2003 | 29 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 2003 | 71 | 0.010 |
Why?
|
| Reed-Sternberg Cells | 1 | 2003 | 46 | 0.010 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 2003 | 45 | 0.010 |
Why?
|
| Chromones | 1 | 2003 | 121 | 0.010 |
Why?
|
| Viscosity | 1 | 2002 | 45 | 0.010 |
Why?
|
| Vinblastine | 1 | 2003 | 462 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2003 | 519 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 335 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 294 | 0.010 |
Why?
|
| Morpholines | 1 | 2003 | 296 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2012 | 4120 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 7091 | 0.010 |
Why?
|
| Leucovorin | 1 | 2002 | 345 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2003 | 704 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2004 | 567 | 0.010 |
Why?
|
| Dacarbazine | 1 | 2003 | 502 | 0.010 |
Why?
|
| Arachidonic Acids | 2 | 1991 | 34 | 0.010 |
Why?
|
| Phorbol Esters | 2 | 1991 | 42 | 0.010 |
Why?
|
| Rats | 3 | 1995 | 6522 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 1472 | 0.010 |
Why?
|
| Viral Load | 1 | 2002 | 482 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 1469 | 0.010 |
Why?
|
| Protein Binding | 1 | 2006 | 3485 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 1497 | 0.010 |
Why?
|
| Prednisone | 1 | 2002 | 1031 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 353 | 0.010 |
Why?
|
| Drug Synergism | 2 | 1993 | 1359 | 0.010 |
Why?
|
| Methotrexate | 1 | 2002 | 1025 | 0.010 |
Why?
|
| Vincristine | 1 | 2002 | 1581 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 3027 | 0.010 |
Why?
|
| Infant | 1 | 2013 | 13936 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 14830 | 0.010 |
Why?
|
| Viper Venoms | 1 | 1996 | 3 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2002 | 1508 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2013 | 16997 | 0.010 |
Why?
|
| Yohimbine | 1 | 1996 | 32 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1996 | 329 | 0.010 |
Why?
|
| Ristocetin | 1 | 1995 | 9 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1995 | 57 | 0.010 |
Why?
|
| Sodium Compounds | 1 | 1995 | 7 | 0.010 |
Why?
|
| Hemin | 1 | 1995 | 29 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 1946 | 0.010 |
Why?
|
| Arsenites | 1 | 1995 | 20 | 0.010 |
Why?
|
| Biopsy | 1 | 2003 | 3385 | 0.010 |
Why?
|
| Serotonin | 1 | 1996 | 288 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 5432 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1996 | 231 | 0.010 |
Why?
|
| Heme | 1 | 1995 | 83 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 1082 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1995 | 255 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 3242 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1995 | 387 | 0.010 |
Why?
|
| Reference Values | 1 | 1995 | 1131 | 0.010 |
Why?
|
| Plasminogen | 1 | 1993 | 29 | 0.010 |
Why?
|
| Mutation | 1 | 2013 | 15904 | 0.010 |
Why?
|
| Nitroarginine | 1 | 1991 | 12 | 0.010 |
Why?
|
| Vasodilation | 1 | 1993 | 216 | 0.010 |
Why?
|
| Child | 1 | 2013 | 30482 | 0.010 |
Why?
|
| Biological Assay | 1 | 1993 | 178 | 0.010 |
Why?
|
| Nigericin | 1 | 1991 | 3 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1993 | 162 | 0.010 |
Why?
|
| Prostaglandin Endoperoxides | 1 | 1991 | 1 | 0.010 |
Why?
|
| Prostaglandins H | 1 | 1991 | 6 | 0.010 |
Why?
|
| Amiloride | 1 | 1991 | 46 | 0.010 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 1 | 1991 | 8 | 0.010 |
Why?
|
| Methylene Blue | 1 | 1991 | 52 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 1991 | 121 | 0.010 |
Why?
|
| Prostaglandin H2 | 1 | 1991 | 14 | 0.010 |
Why?
|
| Binding Sites | 1 | 1995 | 2255 | 0.010 |
Why?
|
| Aorta | 1 | 1995 | 671 | 0.010 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 1991 | 78 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 1991 | 269 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1991 | 613 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2003 | 16645 | 0.010 |
Why?
|
| Calcimycin | 1 | 1989 | 52 | 0.010 |
Why?
|
| Phosphatidylethanolamines | 1 | 1989 | 63 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 1989 | 118 | 0.010 |
Why?
|
| Glycerol | 1 | 1989 | 105 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1989 | 128 | 0.000 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1989 | 154 | 0.000 |
Why?
|
| Endothelium | 1 | 1989 | 156 | 0.000 |
Why?
|
| Exercise | 1 | 1996 | 1208 | 0.000 |
Why?
|
| Aorta, Thoracic | 1 | 1991 | 530 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 7784 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 7897 | 0.000 |
Why?
|